Search
Hymecromone
go.drugbank.com/drugs/DB07118InvestigationalCategories: Compounds used in a research, industrial, or household settingNitecapone
go.drugbank.com/drugs/DB20402ExperimentalNitecapone is a small molecule drug. Nitecapone has a monoisotopic molecular weight of 265.06 Da.
Categories: Compounds used in a research, industrial, or household settingCRx-139
go.drugbank.com/drugs/DB05744ExperimentalCRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. … It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Narazaciclib
go.drugbank.com/drugs/DB19038InvestigationalNarazaciclib is under investigation in clinical trial NCT06351644 (On 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed And/or Refractory Multiple Myeloma).
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalCiglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.
Faropenem medoxomil
go.drugbank.com/drugs/DB05659InvestigationalFaropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).
Oxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].